Multiple sclerosis is a demyelinating disease that affects more than 2.5 million people over world. âCompliance and persistence with continuous, life-long therapy for a chronic condition can be difficult for patients, regardless of the specific therapy employed or condition under treatment. Compliance with medication refers to the extent that a patient adheres to the timing, dosage and frequency prescribed by the physician, while persistence is the âact of continuing the treatment for the prescribed durationâ. The problem of enlisting continued patient cooperation with prescribed therapies requiring self-administration is the most significant threat to the effectiveness of these therapies. When medications must be injected, as is the case with many of the disease-modifying therapies for multiple sclerosis (MS) adherence and compliance may be a barrier to useâ Oleen-Burkey M, Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis.
âIn multiple sclerosis (MS), inflammation-induced damage against the axonal myelin sheath, or demyelination, within the central nervous system (CNS), leads to breakdown of saltatory conduction and progressive disability due to neuronal cell death. There is limited endogenous repair of demyelination in the CNS of MS patients. Moreover, the suppressor T cell responses are deficient in MS and higher antibody responses to microbial agents have been found, both of which may also be due to lower production of downregulatory mechanisms. While treatments are available to limit demyelination, no treatments are available to promote myelin repairâ Mokhtarian F, Multiple Sclerosis: Animal Models and Treatment Options. Journal of Multiple sclerosis publishes review articles related to these issues.
Last date updated on June, 2014